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Abstract
Background/Aim.  Vancomycin-resistant  Enterococci (VRE) is
one of the most important hospital pathogens. The aim of the
study was to evaluate VRE colonization in patients hospitalized at
the Hematology Intensive Care Unit, as well as the associated risk
factors. Methods. A prospective cohort study involved 70 pa-
tients hospitalized at the Intensive Care Unit (ICU), Clinic for
Hematology, Clinical Center of Serbia, Belgrade, during 3 months.
Baseline demographic data, data about antibiotic usage and other
risk factors for VRE colonization during the present and previous
hospitalizations (within 6 months) were recorded for each patient
using the questionnaire. Feces or rectal swab was collected for
culture from patients on admission and at discharge in case when
VRE was not isolated on admission. Enterococci were isolated by
standard microbiological methods. Isolate sensitivity was tested by
disk-diffusion test using 30 Ƭg/mL (BBL) Vancomycin plates ac-
cording to the Clinical and Laboratory Standards Institute (CLSI)
standard. Results. Analysing results showed that 7% of the pa-
tients had been already colonized with VRE upon ICU admis-
sion. The rate of VRE colonization during present hospitalization
was 41.5%. Univariate logistic regression demonstrated the statis-
tically significant differences in diagnosis, length of present stay,
use of aminoglycosides and piperacillin/tazobactam in present
hospitalization, duration of use of carbapenem and piperacil-
lin/tazobactam in present hospitalization between the VRE-
colonized and non-colonized patients. Acute myeloid leukemia
(AML), use of carbapenem in previous hospitalization and dura-
tion of use of piperacillin/tazobactam in present hospitalization
were independent risk factors for VRE-colonized patients ac-
cording to multivariate logistic regression. Conclusion. VRE
colonization rate was high among the patients admitted to hema-
tology ICU.  Rational use of antibiotics and active surveillance
may be helpful preventive measures against the development of
bacterial resistance to antimicrobial agents.
Key words:
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Apstrakt
Uvod/Cilj.  Enterococcus  spp. rezistentan na vankomicin
(VRE) jedan je od najznaÿajnih bolniÿkih patogena. Cilj rada
bio je da se utvrde stope rektalne kolonizacije VRE kod bole-
snika leÿenih u Odeljenju za hematološku intenzivnu negu, i
da se sagledaju faktori rizika od kolonizacije. Metode. Pros-
pektivnom kohortnom studijom obuhvaýeno je 70 bolesnika
leÿenih u periodu od  tri meseca u Klinici za hematologiju
Kliniÿkog centra Srbije u Beogradu. Podaci o demografskim
karatkteristikama bolesnika, upotrebi antibiotika i drugim fa-
ktorima rizika od VRE kolonizacije tokom sadašnje i pretho-
dnih hospitalizacija (tokom 6 meseci) prikupljani su za svakog
bolesnika uz pomoý upitnika. Bolesnicima je uzmana kopro-
kultura ili rektalni bris na prijemu, a prilikom otpusta onim
bolesnicima kod kojih na prijemu nije izolovan VRE. Osetlji-
vost izolata proverena je disk-difuzionim testom sa diskovima
vankomicina 30 Ƭg/mL (BBL) u skladu sa Clinical and
Laboratory Standards Institute  (CLSI) standardima. Rezultati.
Na prijemu je bilo 7% VRE kolonizovnaih bolesnika. Stopa
VRE kolonizacije tokom tekuýe hospitalizacije iznosila je
41,5%. Univarijantna logistiÿka regresija pokazala je statistiÿki
znaÿajne razlike u pogledu  dijagnoze, dužine sadašnje hospi-
talizacije, primeni aminoglikozida i piperacilin/tazobaktama u
sadašnjoj hospitalizaciji, dužini primene karbapenema i pipe-
racilin /tazobaktama u sadašnjoj hospitalizaciji izmeĀu boles-
nika kolonizovanih VRE i nekolonizovanih bolesnika. Multi-
varijantnom logistiÿkom regresijom ustanovljeno je da su
akutna mijeloidna leukemija (AML), primena karbapenema u
prethodnoj hospitalizaciji i dužina primene piperaci-
lin/tazobactama u sadašnjoj hospitalizaciji bili nezavisni fak-
tori rizika od kolonizacije bolesnika VRE. Zakljuÿak. Zabe-
ležena je visoka stopa kolonizacije pacijenata VRE. Racional-
na upotreba antibiotika i aktivni nadzor mogu biti korisne
mere prevencije nastanka rezistencije bakterija na antibiotike.
Kljuÿne reÿi:
enterococcus faecium; vankomicin; lekovi, rezistencija
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Introduction
Bacteria of Enterococcus genus are a significant cause
of hospital-acquired infections (HAI), second among urinary
tract infections (UTI) and third among bacteriemias. There
are many different species of Enterococci. The most preva-
lent species culturated from humans are E. faecalis (the most
common) and E. faecium. Enterococci have both an intrinsic
(nature) and acquired resistance to antibiotics, making them
important nosocomial pathogens. They are intrinsically re-
sistant to penicillin (low level), all cephalosporins, aztreo-
nam, macrolides, and low levels of clindamycin. This natural
resistance is present in all members of species and is chro-
mosomally mediated. Acquired resistance to antibiotics in-
cludes resistance to glycopeptides, ȕ lactamases fluoro-
quinolones, tetracycline, high aminoglycoside doses and gly-
copeptides (vancomycin), as a result of mutations in DNA or
the acquisition of new gene(s). Glycopeptides (vancomycin)
resistance has been seen in around 70–78% of the nosoco-
mial E. faecium population 
1–3. The mechanism of vancomy-
cin resistence is due to preventing the synthesis of peptido-
glycan precursors of the bacterial cell wall by blocking two
steps: the transglycosylation and the transpeptidation 
3. It is
mediated by 5 genes referred to as vanA, which can induce
high level resistance to both vancomycin and teicoplanin;
vanB which is found intrinsically in non-pathogenic entero-
coccal species; vanC; vanD, and vanE. VanA is more widely
distributed 
4.
Vancomycin resistant Enterococcus spp. (VRE) was
first isolated in England and France in 1986 and later on in
other European and countries worldwide 
5. The proportion of
enterococcal bacteremia attributable to VRE in the UK in
2007 was 8.5–12.5% for all enterococci 
6. From 2005 to
2008, a significant decrease in vancomycin resistance was
observed in France (from 2 to 0.6%), Greece (from 37 to
28%), Israel (from 46 to 20%) and Italy (from 19 to 6%).
Ireland, Luxembourg and Greece in 2009 reported resistance
proportions above 25%, while the majority of countries (18
of 26 countries) reported resistant proportions below 7%.
Several countries reported it even below 1% (Bulgaria, Esto-
nia, Finland, France, Norway and Sweden) 
3. During the past
four years, a significant increase was observed only in Aus-
tria. In 2010, 28 EU countries reported 5,577 isolates of E.
faecium, of which 7.4% were resistant to vancomycin. Dur-
ing the four past years, only Latvia reported an increased
trend of these enterococci 
7.
According to the USA National Nosocomial Infections
Surveillance (NNIS), the percentage of enterococcal isolates
resistant to vancomycin increased from 12% in the period
1998–2002 to 28.5% of all isolates in 2003 
8.
VRE can cause different types of HAI, like urinary
tract, surgical site, bacteriemia, meningitis, endocarditis,
most commonly in immunocompromised patients. Entero-
cocci are responsible for high morbidity and mortality rates
in these patients 
9.
Risk factors for VRE colonization and infections are
the following: age, hepatic and renal dysfunction, hemato-
logical diseases, chronic diseases, application of the invasive
diagnostic and therapeutic procedures, stay in intensive care
unit (ICU), abdominal surgery, transplantation, prolonged
hospitalization, and broad-spectrum antibiotic use 
10, 11.
VRE may survive on dry surfaces several weeks (from
7 days to 4 months). Consequently, VRE is most commonly
transmitted in hospitals from person to person by direct con-
tact with personnel and patient’s hands, either from feces,
urine, or blood of a person carrying the organism. It can also
be spread indirectly via hand contact with open wounds, or
with contaminated environments (some parts of medical
equipment and working surfaces contaminated by VRE) 
12.
VRE colonization could persist for years. The colonized pa-
tients are significant reservoirs and sources of contamination
of the environment. VRE is not transmitted through the air 
13.
Methods
This prospective cohort study involved 70 patients hos-
pitalized at the Intensive Care Unit (ICU), Clinic for Hema-
tology, Clinical Center of Serbia, Belgrade, in the period
from September to December 2011. The coproculture or
rectal swab was collected from all the patients on admission
and before discharge.
All the patients were daily observed during their hospi-
talization by an epidemiologist. Clinical charts were system-
atically reviewed and, when necessary, the medical staff was
interviewed. Baseline demographic data, data about antibi-
otic usage and other risk factors for VRE colonization during
present and previous hospitalization were recorded for each
patient using the questionnaire. The following characteristics
related to the patients, and applied diagnostic and therapeuti-
cal procedures were recorded: age, sex, underlying disease,
recent prior hospitalization (within 6 months) and recent an-
timicrobial use, operation, inserted central venous and uri-
nary catheter, mechanical ventilation, antibiotic prophylaxis
and therapy (type of antibiotics), and VRE isolated from
coproculture on admission and the discharge. Surveillance
for VRE infections was carried out during the course of this
study.
VRE isolation and identification
Enterococci were isolated by standard microbiological
methods. Enterococcal identification was based on cultural
characteristics, Gram-stained specimens, mobility in 0.5%
agar, capacity of pigment production and biochemical char-
acteristics. Isolate sensitivity was tested by the disk-diffusion
test using 30 ȝg/mL (BBL) Vancomycin plates according to
the Clinical and Laboratory Standards Institute (CLSI) stan-
dard. The plates were incubated 24 hours at 35°C. The in-
crease in more than one colony or a part of colony was inter-
preted as resistance to vancomycin 
14, 15. E-test was not used
in methodology given than only enterococcal isolates were
recovered and identified from rectal swab or feces for the
purpose of determination of the carrier state.
The descriptive and analytical methods were used for
data processing: Ȥ
2 test (for categorical data) or t-test (for
continuous variables). The results were expressed as percent-
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factors of VRE colonization, the univariate logistic regres-
sion and multivariate logistic regression analyses were used.
Statistical data processing was carried out by SPSS program
(version 10).
Results
Study population and patients characteristics
The study included 70 patients hospitalized at the Clinic
for Hematology, Clinical Center of Serbia during the study
period. Out of all these patients, 5 (7%) were found to have
been already colonized with VRE upon ICU admission. The
VRE positive patients on admission had been hospitalized at
the Clinic for Hematology within the previous six months.
During that hospitalization they received antibiotic therapy.
Out of 65 VRE negative patients on admission, 27
(41.53%) were colonized with VRE strains during current
hospitalization.  The characteristics of these patients are pre-
sented in Table 1. There were 38 (58.4%) males; the mean
age of the subjects was 52.7 years (ranged from 23 to 80
years).
In our study groups of colonized and non-colonized pa-
tients, 18 (66.67%) and 15 (39.47%) had acute myeloid leu-
kemia (AML), respectively. Univariate logistic regression
found a significant difference (OR: 3.06; 95%CI: 1.09–8.60;
p = 0.033) in frequency of this diagnosis between the two
groups of subjects. Furthermore, there was a significant dif-
ference in length of present hospitalization between the
group of colonized patients (median days 35 ± 10.23) and
non-colonized patients (median days 24.4 ± 10.6) (OR: 1.11;
95%CI: 1.04–1.19; p = 0.002).
Univariate logistic regresion analysis failed to find any
significant difference in other characteristics between the
two study groups of patients: age, sex, prior hospitalizations,
antibiotic use, insertion of the urinary and central venous
catheter and infection.
Antibiotic use and duration of antibiotic use
During the present hospitalization, only 15.4% patients
did not receive antibiotics; 43.1% received one or two anti-
biotics and 41.5% three or more antibiotics. Tables 2 and 3
summarize the antibiotic use and duration of antibiotic use
among the patients with and without VRE colonization.  Ac-
cording to univariate logistic regression, the risk factors that
were significantly associated with VRE colonization in-
cluded aminoglycoside use (OR: 3.88; 95%CI: 1.14–13.1; p
= 0.030) and piperacillin/tazobactam use (OR: 4.68; 95%CI:
1.57–13.9; p = 0.005) during present hospitalization (Table
Table 1
Characteristics of the VRE negative patients* on admission and during hospitalization
n (%) of patients
VRE VRE
non-colonized colonized Patients' variables
(n = 38) (n = 27)
OR (95%CI) p
Age (years), mean (± SD) 52.3 (13.0) 53.3 (12.6) 1.00 (0.96–1.04) 0.175
Sex (males/females) 21  (55.26) 17 (62.96) 1.37 (0.50–3.77) 0.847
Diagnosis on admission
acute myeloid leukemia 15 (39.47) 18 (66.66) 3.06 (1.09–8.60) 0.033
non Hodgkin lymphoma 6 (15.78) 1 (3.70 ) 0.20 (0.02–1.81) 0.121
acute lymphocytic leukemia 9 (23.68) 5 (18.51) 0.73 (0.21–2.49) 0.175
chronic lymphocytic leukemia 4 (10.52) 2 (7.40 ) 0.68 (0.11–4.00) 0.669
Length of stay (days), median ± SD
previous hospitalization 8.26 (12.3) 8.56 (13.62) 1.00 (0.96–1.04) 0.927
present hospitalization 24.4 (10.6) 35 (10.23) 1.11 (1.04–1.19) 0.002
previous admission in other hospital 29 (76.31) 18 (66) 1.10 (0.80–1.52) 0.524
Antibiotic use
previous hospitalization 26 (68.42) 20 (74.07) 1.10 (0.80–1.52) 0.524
present hospitalization 34 (89.47) 26 (96.29) 0.75 (0.25–2.27) 0.622
Central venous catheter 1.79 (1.43–2.24) 0.999
previous hospitalization 30 (78.94) 22 (81.48) 0.85 (0.24–2.98) 0.801
present hospitalization 21 (55.26) 19 (70.31) 1.92 (0.67–5.46) 0.220
Bladder catheter
previous hospitalization 1 (2.63 ) 2 (7.40 ) 2.96 (0.25–34.42) 0.386
present hospitalization 11 (28.94) 8 (29.62) 1.03 (0.35–3.05) 0.952
Hospital infection
previous hospitalization 5 (13.15) 2 (7.40) 0.52 (0.09–2.94) 0.467
present hospitalization 24 (63.15) 15 (55.55) 0.72 (0.26–1.99) 0.538
VRE – vancomycin resistent enterococci; *total number of VRE negative patients on admission = 65.Strana 1112 VOJNOSANITETSKI PREGLED Volumen 70, Broj 12
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2). Statistically significant difference (OR: 1.36; 95%CI:
1.94–1.69; p = 0.006) was also noted in the length of pipera-
cillin/tazobactam use between colonized (median days 3.22 ±
3.93) and non-colonized patients (median days 0.87 ± 1.84)
during the present hospitalization (Table 3).
Univariate logistic regresion analysis failed to show any
significant difference in the frequency of use of other antibi-
otics (cephalosporins, quinolones, glycopeptides, antianaero-
bic drugs and cotrimoxazole) and the duration of antibiotic
therapy between the two studied groups of patients.
Table 2
Antibiotic use during previous and present hospitalization (univariate logistic regression)
n (%) of patients
VRE VRE
non-colonized colonized Used antibiotics
(n = 38) (n = 27)
OR (95%CI) p
Cephalosporins
previous hospitalization 1 (2.63) 1 (3.70) 1.42 (0.08–23.7) 0.806
present hospitalization 8 (21.05) 8 (29.62) 1.57 (0.50–4.91) 0.431
Carbapenems
previous hospitalization 2 (5.26) 6 (22.22) 5.14 (0.95–27.8) 0.057
present hospitalization 13 (34.21) 15 (55.55) 2.40 (0.87–8.61) 0.090
Quinolone
previous hospitalization 3 (7.89) 6 (22.22) 3.33 (0.75–14.7) 0.113
present hospitalization 17 (44.73) 12 (44.44) 0.98 (0.36–2.66) 0.988
Glycopeptide
previous hospitalization 1 (2.63) 3 (11.11) 1.05 (0.93–1.19) 0.393
present hospitalization 3 (7.89) 3 (11.11) 1.01 (0.90–1.15) 0.758
Antianaerobic agents
previous hospitalization 1 (2.63) 0 0.97 (0.92–1.02) 0.396
present hospitalization 7 (18.42) 5 (18.51) 1.00 (0.28–3.58) 0.992
Cotrimoxazole
previous hospitalization 1 (2.63) 2 (7.40) 2.96 (0.25–34.4) 0.386
present hospitalization 2 (5.26) 1 (3.70) 0.69 (0.60–8.04) 0.769
Aminoglycosides
previous hospitalization 5 (13.55) 3 (11.11) 0.80 (0.18–3.79) 0.825
present hospitalization 5 (13.55) 10 (37.03) 3.88 (1.14–13.1) 0.030
Piperacilin/tazobactam
previous hospitalization 3 (7.89) 3 (11.11) 1.45 (0.27–7.84) 0.660
present hospitalization 8 (21.05) 15 (55.55) 4.68 (1.57–13.9) 0.005
VRE – vancomycin resistent enterococci.
Table 3
Duration of antibiotic use (univariate logistic regression)
Duration (days), median ± SD
VRE VRE
non–colonized colonized Used antibiotics
(n = 38) (n = 27)
OR (95%CI) p
Cephalosporins
previous hospitalization 0.13 ± 8.11 0.30 ± 1.53 1.13 (0.73–1.75) 0.582
present hospitalization 2.29 ± 5.53 1.96 ± 3.70 0.98 (0.88–1.09) 0.787
Carbapenems
previous hospitalization 0.17 ± 1.13 1.18 ± 2.74 1.39 (0.94–2.05) 0.098
present hospitalization 2.47 ± 4.39 5.04 ± 5.37 1.11 (1.00–1.23) 0.046
Quinolones
previous hospitalization 1.71 ± 6.05 2.48 ± 5.97 1.02 (0.94–1.10) 0.609
present hospitalization 5.13 ± 7.18 3.93 ± 5.96 0.97 (0.90–1.05) 0.473
Glycopeptides
previous hospitalization 0.91 ± 4.77 0.51 ± 1.71 1.04 (0.82–1.32) 0.719
present hospitalization 1.32 ± 3.02 1.52 ± 2.75 1.01 (0.85–1.20) 0.835
Antianaerobic agents
previous hospitalization 0.15 ± 0.82 0.12 ± 0.38 0.70 (0.27–1.83) 0.475
present hospitalization 0.63 ± 1.55 1.07 ± 2.51 1.11 (0.86–1.43) 0.385
Cotrimoxazole
previous hospitalization 0.15 ± 0.82 0.48 ± 1.74 1.39 (0.79–2.43) 0.243
present hospitalization 0.63 ± 1.55 0.22 ± 1.15 1.08 (0.62–1.86) 0.776
Aminoglycoside
previous hospitalization 1.36 ± 4.20 0.44 ± 1.76 0.89 (0.73–1.10) 0.319
present hospitalization 1.45 ± 42.4 1.93 ± 2.74 1.03 (0.90–1.18) 0.605
Piperacilin/tazobactam
previous hospitalization 0.94 ± 4.19 1.25 ± 3.83 1.01 (0.90–1.15) 0.758
present hospitalization 0.87 ± 1.84 3.22 ± 3.93 1.36 (1.94–1.69) 0.006
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Multivariate logistic regresion analysis included all the
values of p < 0.1 (diagnosis, number of hospital days in present
hospitalization, carbapenem use in earlier and present hospitali-
zation, use of aminoglycosides and piperacillin/tazobactam use
in present hospitalization, duration of carbapenem use in previ-
ous and present hospitalization as well as length of piperacil-
lin/tazobactam use in present hospitalization).
The results of multivariate analysis demonstrated that
the diagnosis of the disease (AML), carbapenem use in ear-
lier hospitalization and length of piperacillin/tazobactam use
in present hospitalization were independent risk factors of
colonization of patients with VRE (Table 4).
Infections and pathogens
Data processing did not reveal any significant differ-
ence in the incidence of all HAI (p > 0.05), as well as certain
HAI (urinary tract infections, bloodstream infections and
pneumonia) between the two study groups of patients (Table
5). In the VRE-colonized patients, vancomycin resistant En-
teroccus spp was a cause of urinary tract infections in 4 pa-
tients, while VRE was not isolated as the cause of infection
in the non-colonized patients (Table 6).
Discussion
The patients affected by malignant hemopathies are of-
ten rehospitalized and, therefore possibilly colonized by hos-
pital pathogens including VRE. Immunosuppressed patients
appear to be at special risk for VRE colonization and severe
VRE infections. VRE are a particular problem in the inten-
sive care units of large hospitals where they usually occur.
Our study was designed to evaluate the colonization rate
during hospitalization at the Hematology ICU, colonization
rate on admission, and risk factors of colonization. The re-
Table 4
Risk factors for vancomycin-resistant Enterococci (VRE) colonization
according to multivariate logistic regression analysis
Risk factors B SE OR (95%CI) p
Diagnosis (AML) 0.001 0.001 0.92 (0.99–1.0) 0.048
Antibiotic use
Carbapenems – previous hospitalization 1.651 2.487 5.21 (0.04–6.81) 0.040
Duration of antibiotic use
Piperacillin/tazobactam – present hopsitalization 1.918 0.884 6.80 (1.20–3.85) 0.030
AML – acute myeloid leukemia.
Table 5
Infection in vancomycin-resistant Enterococci (VRE) – colonized  patients in present hospitalization
n (%) of patients
Hospital–acquired VRE non–colonized VRE colonized
infections (HAI) (n = 38) (n = 27)
Total patients
n (%)
Urinary tract infections 12 (31.6) 8 (29.6) 20 (30.8)
Bloodstream infections 8 (21.1) 3 (11.1) 11 (16.9)
Pneumonia 0 (0.0) 2 (7.40) 2 (3.1)
Without HAI 18 (47.3) 14 (51.9) 32 (49.2)
Total n (%) 38 (100.0) 27 (100.0) 65 (100.0)
Table 6
Cases of infection in the vancomycin-resistant Enterococci (VRE) – colonized and non–colonized patients in present
hospitalization
n (%) of patients
VRE VRE
non–colonized colonized
Hospital acquired
infection ( HAI)
(n = 38) (n = 27)
Total patients
n (%)
Urinary tract infection
Esherichia coli 5 (41.6) 0 (0.0) 5 (25.0)
Klebsiella spp. 5 (41.6) 1 (12.5) 6 (30.0)
Enterococcus spp.(vancomycin sensitive) 1 (8.3) 3 (37.5) 4 (20.0)
Enterococcus spp.(vancomycin resistent) 0 (0.0) 4 (50.0) 4 (20.0)
Providentia retgery 1 (8.3 ) 0 (0.0) 1 (5.0)
Total patients, n (%) 12 (60) 8 (40) 20 (100.0)
Bloodstream infection CNS
* 4 (50.0) 2 (66.6) 6 (54.5)
Klebsiella spp 1 (12.5) 0 (0.0) 1 (9.09)
Pseudomonas spp. 1 (12.5) 0 (0.0) 1 (9.09)
Stenotrophomonas maltophilia 1 (12.5) 0 (0.0) 1 (9.09)
Acinetobacter spp. 1 (12.5) 0 (0.0) 1 (9.09)
Esherichia coli 0 1 (33.3) 1 (9.09)
Total patients, n (%) 8 (72.72) 3 (27.28) 11 (100.0)
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sults of this study showed that 7% of the patients were VRE
positive on admission (VRE isolated from feces culture or
rectal swab). The colonization rate during ICU hospitaliza-
tion was 41.5%.
A relatively small number of articles described VRE
colonization in hematological patients 
10, 16–19. However, En-
teroccoci have recently emerged as nosocomial agents, espe-
cially in patients with hematooncological diseases. The
studies from France and the Netherlands showed that 37%,
and 49% of hematological patients were colonized by VRE,
respectively
 16, 17. Contrary to these results, VRE colonization
in the USA immunocompromised patients was reported in
considerably lower percentage. It was noted that out of 2,115
hematological patients, 4.7% patients had verified rectal
VRE colonization. Among all colonized patients, 5.4% were
patients with leukemia, 4.9% with hematopoietic stem cell
transplantation recipients, and 2.2% with lymphoma 
20. In
other study which was carried out on the hematologyoncol-
ogy unit, 7.7% of patients, predominantly with hematologic
malignancies, were colonized or infected with VRE during
the study period 
21. A much higher rate of VRE colonization
in our study (41.5%) is probably the result of the lack of
contact isolation measures and the increased use of antibiot-
ics. This is supported by the fact that only 15% of patients
did not receive antibiotics during present hospitalization.
Many years ago, it was demonstrated that 5–50% of all
antibiotic prescriptions are considered inappropriate which
can cause the emergence and dissemination of resistant or-
ganisms. However, there is not standard treatment protocol
for antibiotic prescription in our country. Beside that, the an-
tibiotics were until recently available over-the-counter in the
pharmacies. Antibiotic prescription is frequently done with-
out antibiograms or even without bacteriology isolation of
pathogens. All of the above mentioned can lead to high rates
of bacterial resistance to antibiotics. It is important to em-
phasize that there is an increasing trend of vancomycin re-
sistance in our country 
22.
Our study failed to find any association of sex and the
age and development of VRE fecal colonization at discharge.
Our findings are consistent with the results of similar studies
conducted in Korea 
23. On the contrary, a study carried out at
the Thessaloniki University Clinic confirmed that VRE colo-
nization was significantly more frequent in patients older
than 60 years of age 
24.
Analysis of our results showed that VRE colonization
was significantly more frequent in patients with AML. Mul-
tivariate regression analysis demonstrated that AML was an
independent risk factor for VRE colonization. Similar results
were found in other studies as well 
21. It can be explained by
the long length of hospitalization. Namely, duration of hos-
pital stay of our patients with AML ranged from 28 to 40
days, in distinction from the patients with acute lymphocytic
leukemia (ALL), non-Hodgkin lymphoma (NHL) and
chronic lymphocytic leukemia (HLL) who were hospitalized
during significantly shorter period. From the aspect of a cli-
nician this may be explained by the length of therapy proto-
col application. Besides other risk factors, the length of hos-
pital stay is considered as one of most important risk fac-
tor 
10, 11, 24. Accordingly, AML patients are at higher risk of
colonization than patients with shorter hospitalization. The
results of this study are only the introduction to more com-
prehensive and detailed analysis of the problem not only in
hematological, but also in other immunocompromised pa-
tients.
Our study failed to find any significant difference in
previous hospitalization between the two studied groups of
patients, contrary to the results of other studies 
20, 25. How-
ever, mean length of present hospitalization in VRE-
colonized patients was significantly longer in relation to non-
colonized patients, ie 35 vs 24 days.
The results of several studies showed that the use of
glycopeptides, second and third generation cephalosporins
and antianaerobic antibiotics are associated with the pa-
tients colonized with VRE
 25, 26. Only few studies analyzed
the association of quinolone use and VRE colonization.
Our study failed to establish any significant difference in
the use and length of use of antibiotics from the group of
quinolones (ciprofloxacin) between the two groups of sub-
jects what is compatible with the findings obtained in other
studies 
25.
Several studies on the effect of carbapenem as the risk
factor for VRE colonization did not show any significant dif-
ference in the use of these antibiotics between VRE-
colonized and non-colonized patients 
20, 26. However, in other
studies prior carbapenem use was a significant risk factor for
VRE colonization 
24, 25. Our study showed that there was a
difference in the duration of the use of antibiotics from car-
bapenem group (imipenem and meropenem) between two
groups of subjects in repeated hospitalization. Mean duration
of carbapenem use in the VRE-colonized and in non-
colonized patients in the repeated hospitalization was 5 and
2.47 days, respectively. Moreover, carbapenem use in previ-
ous hospitalization was an independent risk factor of VRE
colonization.
Vancomycin is a glycopeptide antibiotic that is used to
treat infections caused by Gram-positive bacteria. For many
years, it has traditionally been reserved as a drug of “last re-
sort”, used to treat severe infections for which other antibi-
otics had failed. Vancomycin use has increased linearly in
the last decades, especially for infections related to the pres-
ence of indwelling vascular catheter which is the case with
hematology-oncology patients. Vancomycin is not recom-
mended for regular antibioprophylaxis in surgery. However,
a growing number of infections caused by Staphylococcus
aureus resistant to meticillin has led to the widespread use of
vancomycin in hospitals. The results of studies on associa-
tion of vancomycin use and VRE colonization and infection
have been controversial. A meta-analysis of 20 studies
showed that the use of vancomycin increased the risk of
VRE colonization by 4.5 times 
27. Using the multivariate
analysis, Ostrowsky et al. 
28, in contrast, demonstrated that
there was no association between the vancomycin use and
VRE colonization. In addition, the results of recent system-
atic review did not determine a potential role for vancomycin
usage reduction in controlling VRE colonization 
29. Our
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of vancomycin use and length of its use between the two
groups of patients.
Analysing a study on the effect of use of antibiotics
from the group of aminoglycosides failed to find any signifi-
cant difference in the frequency of use of these antibiotics
between VRE-colonized and non-colonized patients 
17. On
the contrary, our results showed a significant difference in
the use of aminoglycoside antibiotics between the two
groups of subjects during repeated hospitalization. In the
VRE-colonized group, 37% of the patients were adminis-
tered aminoglycoside antibiotics while in the non-colonized
group 13% of the patients received these antibiotics.
Analysing of our data showed that the VRE-colonized
patients received piperacillin/tazobactam in a significantly
higher percentage (55%) then non-colonized patients (21%).
An average length of piperacillin/tazobactam use in the VRE-
colonized and non-colonized patients during the present hos-
pitalization was 3.22 and 0.87 days, respectively. Moreover,
the use of this antibiotic in present hospitalization was an in-
dependent risk factor of VRE colonization. The incidence of
VRE was positively correlated with the use of piperacil-
lin/tazobactam or beta-lactam agents in other studies as well 
30.
As the part of normal fecal flora, Enteroccoci were not
traditionally considered as important nosocomial pathogens.
But, they have emerged as increasingly important pathogens
with increased resistance to antibiotics. VRE become one of
the leading causes of HAI, especially of urinary tract and
bloodstream infections. VRE commonly colonise, but less
frequently cause the infections. However, colonization pre-
cedes most infections. In our study, VRE was a cause of UTI
in the colonized patients but not in the non-colonized pa-
tients. VRE infections are not more virulent than other en-
teroccocal infections. But, VRE infections are very problem-
atic for treatment. Enterococci are the most frequent cause of
UTI. During one year of surveillance, organized by the Na-
tional Healthcare Safety Network in the USA there was
found that Enteroccocus spp was third the most frequent
pathogen of HAI participated with 12% in the overall num-
ber of pathogenic isolates. Regarding rank-order distribution,
it was at second position for bloodstream infections and at
third position for UTI.  E. faecium and E. faecalis showed a
high proportion of vancomycin resitance: 98.4–99.5% and
91.9–98.4%, respectively 
31.
Conclusion
VRE colonization rate was high among patients admit-
ted to hematology ICU.  Rational use of antibiotics and ac-
tive surveillance may be helpful preventive measures against
the development of bacterial resistance to antimicrobial
agents.
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